MedTrace Logo

Open Label Study of Everolimus (RAD001) in Patients With Segmental Overgrowth Syndrome

NCT02569125 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2017-09-28

No results posted yet for this study

Summary

This is an open-label, multicenter, single-arm, phase II clinical trial of Everolimus (RAD001) in patients with segmental overgrowth syndrome.

Conditions

  • Segmental Overgrowth Syndrome

Interventions

DRUG

Everolimus

4.5 mg/m² daily

Sponsors & Collaborators

  • Clinical Trials Unit Freiburg

    collaborator OTHER

  • Jochen Roessler

    lead OTHER

Principal Investigators

  • Jochen Roessler, Professor · University Hospital Freiburg

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2016-01-31
Completion
2016-02-29

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02569125 on ClinicalTrials.gov